Vall d'Hebron Institute of Oncology
Barcelona, Spain
Dr Raquel Perez-Lopez is an experienced academic radiologist trained at the Royal Marsden Hospital and the Institute of Cancer Research in London (UK). Her PhD studies enabled her to identify the value of whole-body diffusion-weighted MRI as a prognostic and response biomarker of bone metastases in prostate cancer, that in turn led to the completion of the first prospective clinical trial in this context. Importantly, the studies in which she collaborated over her PhD resulted in over fifteen manuscripts that she first or co-authored in prestigious titles including NEJM, Cell, Cancer Discovery and Radiology.
Raquel joined VHIO in late 2017 as Team Leader of VHIO’s newly established Radiomics Group. The group’s efforts center on advancing precision imaging in personalized medicine, towards ultimately improving outcomes for cancer patients by applying mathematical methods to image processing and artificial intelligence in the biomedical field.
Dr. Perez-Lopez is co-investigator of several international research consortia: 1) CCE-DART, aiming to optimize clinical trial design by the implementation of novel predictive and early response imaging biomarkers; 2)COLOSSUS, this Horizon 2020-supported project aims to unravel new subtypes of RAS-mutant CRC. Dr Perez-Lopez leads the medical imaging area of this project and coordinates the application of radiomics and ML models for exploring imaging phenotypes characteristic of new RAS-mutant CRC subtypes. She is also an active member of the Cancer Core Europe-Imaging Task Force and coordinates several multicentric trials, including the PREDICT study funded by the CRIS-Foundation, aiming to develop response biomarkers in cancer immunotherapy with CT-radiomics and functional MRI.
Friday, June 30, 2023
08:00 – 08:20 CEST
Friday, June 30, 2023
08:40 – 09:00 CEST
Friday, June 30, 2023
09:00 – 09:25 CEST